SCHEMBL2018917

SCHEMBL2018917

CCCCCCCCCCCCCCCCCCOc1cc(C(=O)OC)cc(OCCCCCCCCCCCCCCCCCC)c1OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.60

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 5/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15726531 1.00 SMPD1 (0.53) SMPD1
SCHEMBL3797840 1.00 SMPD1 (0.53) SMPD1
SCHEMBL31481564 1.00 SMPD1 (0.53) SMPD1
SCHEMBL14085627 1.00 SMPD1 (0.53) SMPD1
SCHEMBL15731929 1.00 SMPD1 (0.53) SMPD1
SCHEMBL31111470 1.00 SMPD1 (0.53) SMPD1
SCHEMBL28591699 0.98 SMPD1 (0.51) SMPD1
SCHEMBL7997525 0.94 SLC6A5 (0.50) SMPD1
SCHEMBL38650614 0.92 SMPD1 (0.56) SMPD1
SCHEMBL31174418 0.92 SMPD1 (0.47) SMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741411-A2 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2026-05-13 EP disclosed
US-12559517-B2 Oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2026-02-24 US disclosed
EP-3676265-B1 METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES ELANCO ANIMAL HEALTH GMBH (DE) 2025-08-20 EP disclosed
US-20250019360-A1 METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES ELANCO ANIMAL HEALTH GMBH (DE) 2025-01-16 US disclosed
CN-113717239-B Precipitation accelerator and precipitation method using the same 味之素株式会社 2024-12-24 CN disclosed
US-12122759-B2 Method for the synthesis of cyclic depsipeptides ELANCO ANIMAL HEALTH GMBH (DE) 2024-10-22 US disclosed
EP-4332111-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND Nippon Shinyaku Co., Ltd. (JP) 2024-03-06 EP disclosed
CN-116063365-A Method for preparing oligonucleotide and nucleoside, nucleotide or oligonucleotide 味之素株式会社 2023-05-05 CN disclosed
EP-3263579-B1 PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED AJINOMOTO KK (JP) 2022-11-30 EP disclosed
EP-4049991-A1 PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED AJINOMOTO CO., INC. (JP) 2022-08-31 EP disclosed
EP-3263579-A1 PRECIPITATION ACCELERATOR AND PRECIPITATION METHOD IN WHICH SAME IS USED AJINOMOTO CO., INC. (JP) 2018-01-03 EP disclosed
US-20170320904-A1 PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED AJINOMOTO CO., INC. (JP) 2017-11-09 US disclosed
US-20170320904-A1 PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED AJINOMOTO CO., INC. (JP) 2017-11-09 US disclosed
WO-2017161293-A1 POLYCATENAR LIGANDS AND HYBRID NANOPARTICLES MADE THEREFROM RHODIA OPERATIONS (FR) 2017-09-21 WO disclosed
US-9206230-B2 Benzylic compound AJINOMOTO CO., INC. (JP) 2015-12-08 US disclosed
US-20140371424-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2014-12-18 US disclosed
US-8859732-B2 Benzylic compound AJINOMOTO CO., INC. (JP) 2014-10-14 US disclosed
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 EP disclosed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 US disclosed
JP-2000044493-A PROTECTING GROUP FOR SYNTHESIZING COMPOUND LIBRARY ASAHI CHEM IND CO LTD 2000-02-15 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160433-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN SMPD1 3227/4885
US-20140371424-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN SMPD1 3227/4885
US-20170320904-A1 PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED SP1, MED25, CTCF SMPD1 4221/4885
US-12122759-B2 Method for the synthesis of cyclic depsipeptides DNPEP, NPEPPS, PREP SMPD1 1100/4885
US-20250019360-A1 METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES DNPEP, NPEPPS, PREP SMPD1 1100/4885
US-12559517-B2 Oligonucleotide manufacturing method POLL, IGF2BP1, POLI SMPD1 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.